Nanologica AB (publ) (Nanologica AB) aktie
NICA.ST
RealtidNanologica AB
Market Cap
$176,220,640
Om Nanologica AB (publ) (Nanologica AB) aktie
Nanologica AB (publ), a life science tools company, develops, manufactures, and sells nanoporous silica particles in China, India, Turkey, the United States, and internationally. The company offers NLAB Saga, a silica-based purification media for preparative chromatography that is developed for the purification of peptide drugs, such as insulin and GLP-1 analogues; NLAB Idun, an ion exchange product for robust, reproducible, and efficient downstream purification of GLP-1 analogues and other peptides; NLAB Idun SP, a strong cation exchanger with sulfopropyl groups as ligands; NLAB Idun Q, a strong anion exchanger with a quaternary amine ligand; and NLAB Siv, a non-silica-based media for purification by preparative chromatography used for products outside the peptide range. It also provides high-performance liquid chromatography, a separation method based on different substances in a solution passing through a column at different paces; and analytical chromatography, an analysis method in the pharmaceutical and food industries. The company's products are used to purify substances with a focus on peptide drugs for the treatment of diabetes and obesity. It serves pharmaceutical companies, as well as contract manufactures of insulin and insulin analogues, GLP-1 analogues, biosimilars to insulin and GLP-1 analogues, and other peptide drugs. Nanologica AB (publ) was incorporated in 2004 and is headquartered in Södertälje, Sweden.
Selskabsinformation
151 36 Södertälje, Sweden
Analytikernes aktieanbefalinger
Denne oversigt giver et hurtigt indblik i, hvordan analytikere vurderer aktiens potentiale baseret på deres seneste analyser og kursmål.